Anthony Germinaro Joins PetVivo Holdings, Inc. as a Field Veterinary Business Development Manager
August 19 2024 - 10:10AM
PetVivo Holdings, Inc. (OTCB: PETV & PETVW) (the "Company") an
emerging biomedical device company focused on the commercialization
of innovative medical devices and therapeutics for companion
animals and animal athletes is pleased to announce that Anthony
Germinaro has accepted a position with the Company as its new Field
Veterinary Business Development Manager for the for the Southwest
Region of the United States.
"Adding Anthony to our sales and distribution
team provides a tremendous boost to PetVivo’s commercialization
efforts,” said John Lai, Chief Executive Officer of PetVivo
Holdings, Inc. “Anthony brings to PetVivo a wealth of veterinary
in-clinic experience that is extraordinarily valuable to our
efforts in advancing awareness of our innovative product Spryng™
with OsteoCushion™ technology to veterinarians throughout the
Southwest Region of the United States.”
Anthony Germinaro brings to PetVivo more than 14
years of experience in the animal health Industry. Anthony has
achieved success and gained significant experience in veterinary
clinics as well as sales of animal health products serving roles
ranging from lead ultrasound technician to practice manager.
Anthony’s career has produced valuable experience in sales and
veterinary clinic management with entities such as Dr. Fossum’s Pet
Care, Anivive Life Sciences, Black Mountain Veterinary Cardiology,
Banfield Pet Hospital and VetMed.
“Joining PetVivo as a new Field Veterinary
Business Development Manager is an incredible opportunity for me to
continue my passion, leverage my industry knowledge, and positively
impact the quality of life for horses and companion animals. said
Anthony Germinaro. “I am thrilled to have the opportunity to join
the PetVivo sales and distribution team. It is a pleasure to be
part of a company that possesses technology that has been shown to
improve the medical outcomes of animals suffering from lameness and
other joint related afflictions, such as osteoarthritis,”
About PetVivo Holdings
PetVivo Holdings, Inc. (OTCQB: PETV, PETVW) is a
biomedical device company focused on the manufacturing,
commercialization and licensing of innovative medical devices and
therapeutics for companion animals. The company is pursuing a
strategy of developing and commercializing human therapies for the
treatment of companion animals in capital and time efficient ways.
A key component of this strategy is an accelerated timeline to
revenues for veterinary medical devices that can enter the market
much earlier than more stringently regulated human pharmaceuticals
and biologics.
PetVivo has developed a robust pipeline of
products for the medical treatment of animals and people, with a
portfolio of 21 patents that protect the company's biomaterials,
products, production processes and methods of use. The company’s
commercially launched flagship product, Spryng™ with OsteoCushion™
Technology, is a veterinarian-administered, intra-articular
injectable designed for the management of lameness and other joint
related afflictions, including osteoarthritis, in cats, dogs and
horses.
For more information about PetVivo and its
revolutionary Spryng with OsteoCushion Technology, email
info1@petvivo.com or visit petvivo.com or sprynghealth.com.
Disclosure Information
PetVivo uses and intends to continue to use its
Investor Relations website as a means of disclosing material
nonpublic information and for complying with its disclosure
obligations under Regulation FD. Accordingly, investors should
monitor the company’s Investor Relations website, in addition to
following the company’s press releases, SEC filings, public
conference calls, presentations and webcasts.
Forward-Looking commercial
Statements
The foregoing information regarding PetVivo
Holdings, Inc. (the “Company”) may contain “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934,
each as amended. Forward-looking statements include all statements
that do not relate solely to historical or current facts, including
without limitation the Company’s proposed development and
commercial timelines, and can be identified by the use of words
such as “may,” “will,” “expect,” “project,” “estimate,”
“anticipate,” “plan,” “believe,” “potential,” “should,” “continue”
or the negative versions of those words or other comparable words.
Forward-looking statements are not guarantees of future actions or
performance. These forward-looking statements are based on
information currently available to the Company and its current
plans or expectations and are subject to a number of uncertainties
and risks that could significantly affect current plans. Risks
concerning the Company’s business are described in detail in the
Company’s Annual Report on Form 10-K for the year ended March 31,
2024 and other periodic and current reports filed with the
Securities and Exchange Commission. The Company is under no
obligation to, and expressly disclaims any such obligation to,
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
Company Contact John Lai, CEO
PetVivo Holdings, Inc. Email Contact Tel (952) 405-6216
Investor Contact Ronald Both or
Grant Stude CMA Investor Relations Tel (949) 432-7566 Email
contact
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Nov 2024 to Dec 2024
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Dec 2023 to Dec 2024